表紙
市場調査レポート

ポリオ : パイプライン分析

Polio - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 192781
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
ポリオ : パイプライン分析 Polio - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 69 Pages
概要

ポリオは高度に感染性の高いウイルス性疾患で、神経系を冒して、数時間のうちに全身がまひ状態に陥る、という特徴があります。主な症状として、発熱や倦怠感、吐き気、頚部の硬直、手足の痛みなどが挙げられます。ワクチンの使用などの予防手段が、ポリオに対して効果的です。

当レポートでは、世界各国でのポリオ(小児まひ、急性灰白髄炎)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

ポリオの概要

治療薬の開発

  • ポリオ向けパイプライン製品:概要
  • ポリオ向けパイプライン製品:比較分析

各企業で開発中のポリオ治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ポリオ治療薬:開発中の製品の一覧(企業別)

ポリオ治療薬の開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • Codagenix, Inc.
  • Crucell N.V.
  • 第一三共
  • Grifols, S.A.
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • Taiga Biotechnologies, Inc.

ポリオ:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (ジフテリア + 破傷風 + 百日咳 (非細胞) + ポリオウィルス) ワクチン
  • ジフテリア + 破傷風 + 百日咳 (非細胞) + インフルエンザ菌 血清型 B + ポリオワクチン
  • ジフテリア + 破傷風 + 百日咳 (全細胞) + インフルエンザ菌 血清型 B + ポリオ (五価) ワクチン
  • ジフテリア + 破傷風 + 百日咳 (全細胞) + B型肝炎 + インフルエンザ菌 血清型 B + ポリオ (六価) ワクチン
  • ジフテリア + 破傷風 + 百日咳 (全細胞) + ポリオ + インフルエンザ菌 血清型 B + B型肝炎 + 髄膜炎菌性 血清型 C (七価) ワクチン
  • ジフテリア + 破傷風+ 百日咳 (全細胞l) + B型肝炎 + ポリオ + インフルエンザ菌 B型 (六価) ワクチン
  • 免疫グロブリン(ヒト)
  • IPVGVI-3000
  • ポリオ (二価) ウイルス様粒子ワクチン
  • ポリオ (一価) ワクチン
  • ポリオ セービン ワクチン
  • ポリオワクチン
  • ポリオワクチン
  • ポリオワクチン
  • ポリオワクチン
  • ポリオワクチン 1, 2, 3型 (一価)
  • ポリオワクチン
  • PR-5I
  • 腫瘍・感染症向けタンパク質
  • VN-0105

ポリオ治療薬:パイプライン製品の最新動向

ポリオ治療薬:開発が休止状態の製品

ポリオ治療薬:開発が中止された製品

ポリオ関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7340IDB

Summary

Global Markets Direct's, 'Polio - Pipeline Review, H2 2015', provides an overview of the Polio's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polio
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Polio
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polio Overview
  • Therapeutics Development
    • Pipeline Products for Polio - Overview
    • Pipeline Products for Polio - Comparative Analysis
  • Polio - Therapeutics under Development by Companies
  • Polio - Therapeutics under Investigation by Universities/Institutes
  • Polio - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Polio - Products under Development by Companies
  • Polio - Products under Investigation by Universities/Institutes
  • Polio - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Bharat Biotech International Limited
    • Biological E. Limited
    • Boryung Pharmaceutical Co., Ltd.
    • Codagenix, Inc.
    • Crucell N.V.
    • Daiichi Sankyo Company, Limited
    • Grifols, S.A.
    • Panacea Biotec Limited
    • Sanofi Pasteur SA
    • Sentinext Therapeutics Sdn Bhd
    • Sinovac Biotech Ltd.
    • Taiga Biotechnologies, Inc.
  • Polio - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPVGVI-3000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio (bivalent) virus like particle vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio [sabin] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine [types 1, 2, 3] (monovalent) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • poliomyelitis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PR-5I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein for Oncology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Polio - Recent Pipeline Updates
  • Polio - Dormant Projects
  • Polio - Discontinued Products
  • Polio - Product Development Milestones
    • Featured News & Press Releases
      • Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Polio, H2 2015
  • Number of Products under Development for Polio - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Polio - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
  • Polio - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015
  • Polio - Pipeline by Bharat Biotech International Limited, H2 2015
  • Polio - Pipeline by Biological E. Limited, H2 2015
  • Polio - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015
  • Polio - Pipeline by Codagenix, Inc., H2 2015
  • Polio - Pipeline by Crucell N.V., H2 2015
  • Polio - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Polio - Pipeline by Grifols, S.A., H2 2015
  • Polio - Pipeline by Panacea Biotec Limited, H2 2015
  • Polio - Pipeline by Sanofi Pasteur SA, H2 2015
  • Polio - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2015
  • Polio - Pipeline by Sinovac Biotech Ltd., H2 2015
  • Polio - Pipeline by Taiga Biotechnologies, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Polio Therapeutics - Recent Pipeline Updates, H2 2015
  • Polio - Dormant Projects, H2 2015
  • Polio - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Polio, H2 2015
  • Number of Products under Development for Polio - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top